
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Protecting Sensitive Information in Life Sciences Organizations: Top Three Misconceptions that Put Companies at Risk-Brainloop Whitepaper






